Education
About Us
Working with TipRanks
Follow Us
Fulgent Genetics (FLGT)
:FLGT
FLGT Stock Chart & Stats
$23.11
-$0.14(-0.74%)
At close: 4:00 PM EST
$23.11
-$0.14(-0.74%)
Day’s Range― - ―
52-Week Range$14.57 - $28.81
Previous CloseN/A
Volume61.15K
Average Volume (3M)225.71K
Market Cap
$806.85M
Enterprise ValueN/A
Total Cash (Recent Filing)$375.80M
Total Debt (Recent Filing)$7.99M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Feb 26, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding30,609,043
10 Day Avg. Volume287,259
30 Day Avg. Volume225,712
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.49
Price to Sales (P/S)1.97
P/FCF Ratio-29.00
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fulgent Genetics News
FLGT FAQ
What was Fulgent Genetics’s price range in the past 12 months?
Fulgent Genetics lowest stock price was $14.57 and its highest was $28.81 in the past 12 months.
What is Fulgent Genetics’s market cap?
Fulgent Genetics’s market cap is $806.85M.
When is Fulgent Genetics’s upcoming earnings report date?
Fulgent Genetics’s upcoming earnings report date is Feb 26, 2026 which is in 105 days.
How were Fulgent Genetics’s earnings last quarter?
Fulgent Genetics released its earnings results on Nov 07, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of -$0.224 by $0.364.
Is Fulgent Genetics overvalued?
According to Wall Street analysts Fulgent Genetics’s price is currently Overvalued.
Does Fulgent Genetics pay dividends?
Fulgent Genetics does not currently pay dividends.
What is Fulgent Genetics’s EPS estimate?
Fulgent Genetics’s EPS estimate is -0.06.
How many shares outstanding does Fulgent Genetics have?
Fulgent Genetics has 30,609,043 shares outstanding.
What happened to Fulgent Genetics’s price movement after its last earnings report?
Fulgent Genetics reported an EPS of $0.14 in its last earnings report, beating expectations of -$0.224. Following the earnings report the stock price went up 18.153%.
Which hedge fund is a major shareholder of Fulgent Genetics?
Currently, no hedge funds are holding shares in FLGT
Fulgent Genetics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
FLGT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 18.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $121.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.70%
12-Months-Change
Fundamentals
Return on Equity
-3.80%
Trailing 12-Months
Asset Growth
-2.63%
Trailing 12-Months
Company Description
Fulgent Genetics
Fulgent Genetics (FLGT) is a leading genomic testing company that specializes in providing comprehensive genetic testing services. The company operates primarily in the healthcare sector, focusing on advanced molecular diagnostics, including genetic testing for various conditions such as inherited diseases, infectious diseases, and oncology. Fulgent offers a wide range of services, including next-generation sequencing (NGS) and custom testing solutions, catering to both healthcare providers and patients, with a mission to improve patient outcomes through precision medicine.
FLGT Company Deck
FLGT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant growth in laboratory services and advancements in therapeutic development. Despite some challenges with Anatomic Pathology collections and a GAAP loss, the company's overall financial health and strategic initiatives suggest strong momentum.View all FLGT earnings summariesTechnical Analysis
Ownership Overview
35.50% Insiders
11.39% Mutual Funds
<0.01% Other Institutional Investors
38.55% Public Companies and
Individual Investors